Is More Not Better?
作者： Emily K. Bergsland
DOI: 10.1016/J.HOC.2014.09.002
关键词: Medicine 、 Vascular endothelial growth factor 、 Adjuvant therapy 、 Regimen 、 Colorectal cancer 、 Oncology 、 Combination chemotherapy 、 Systemic therapy 、 Internal medicine 、 Adverse effect 、 Targeted therapy 、 Hematology
摘要: The treatment of colorectal cancer has evolved dramatically in recent years with the availability new chemotherapeutic agents and inhibitors vascular endothelial growth factor- epidermal factor-signaling pathways. incremental benefit each individual line therapy for advanced disease is relatively small. Advances our ability to select patients should improve cost-effectiveness strategies (avoiding unnecessary toxicity who are unlikely accepting potential adverse events stand most from a given regimen).
elsevier.com
sci-hub.se 参考文章(123)
J. Cassidy, L. Saltz, C. Twelves, E. Van Cutsem, P. Hoff, Y. Kang, J.P. Saini, F. Gilberg, D. Cunningham, Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients Annals of Oncology. ,vol. 22, pp. 2604- 2609 ,(2011) , 10.1093/ANNONC/MDR031
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent, None, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet. ,vol. 381, pp. 303- 312 ,(2013) , 10.1016/S0140-6736(12)61900-X
Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas Nikitas, Christos N Papandreou, George Pentheroudakis, Eleni Timotheadou, Angelos Koutras, Joseph Sgouros, Dimitrios Bafaloukos, George Klouvas, Theofanis Economopoulos, Konstantinos N Syrigos, George Fountzilas, XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis BMC Cancer. ,vol. 12, pp. 271- 271 ,(2012) , 10.1186/1471-2407-12-271
L. Fornaro, S. Lonardi, G. Masi, F. Loupakis, F. Bergamo, L. Salvatore, C. Cremolini, M. Schirripa, C. Vivaldi, G. Aprile, A. Zaniboni, S. Bracarda, G. Fontanini, E. Sensi, C. Lupi, M. Morvillo, V. Zagonel, A. Falcone, FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) Annals of Oncology. ,vol. 24, pp. 2062- 2067 ,(2013) , 10.1093/ANNONC/MDT165
Issa J. Dahabreh, Teruhiko Terasawa, Peter J. Castaldi, Thomas A. Trikalinos, Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer Annals of Internal Medicine. ,vol. 154, pp. 37- 49 ,(2011) , 10.7326/0003-4819-154-1-201101040-00006
Michael J. O'Connell, A Phase III Trial of 5-fluorouracil and Leucovorin in the Treatment of Advanced Colorectal Cancer. A Mayo Clinic/North Central Cancer Treatment Group Study Cancer. ,vol. 63, pp. 1026- 1030 ,(1989) , 10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert Ross, Fairooz Kabbinavar, None, BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER The New England Journal of Medicine. ,vol. 350, pp. 2335- 2342 ,(2004) , 10.1056/NEJMOA032691
Jean-Pierre Gérard, David Azria, Sophie Gourgou-Bourgade, Isabelle Martel-Lafay, Christophe Hennequin, Pierre-Luc Etienne, Véronique Vendrely, Eric François, Guy de La Roche, Olivier Bouché, Xavier Mirabel, Bernard Denis, Laurent Mineur, Jean-François Berdah, Marc-André Mahé, Yves Bécouarn, Olivier Dupuis, Gérard Lledo, Jean-François Seitz, Laurent Bedenne, Béata Juzyna, Thierry Conroy, Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer Journal of Clinical Oncology. ,vol. 30, pp. 4558- 4565 ,(2012) , 10.1200/JCO.2012.42.8771
Eric Van Cutsem, Roberto Labianca, György Bodoky, Carlo Barone, Enrique Aranda, Bernard Nordlinger, Claire Topham, Josep Tabernero, Thierry André, Alberto F. Sobrero, Enrico Mini, Richard Greil, Francesco Di Costanzo, Laurence Collette, Laura Cisar, Xiaoxi Zhang, David Khayat, Carsten Bokemeyer, Arnaud D. Roth, David Cunningham, Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Journal of Clinical Oncology. ,vol. 27, pp. 3117- 3125 ,(2009) , 10.1200/JCO.2008.21.6663
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg, Claus-Christoph Steffens, Vicente Alonso-Orduña, Christoph Schlichting, Irmarie Reyes-Rivera, Belguendouz Bendahmane, Thierry André, Stefan Kubicka, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncology. ,vol. 14, pp. 29- 37 ,(2013) , 10.1016/S1470-2045(12)70477-1